GRIFOLS, S.A. «12345...» Page 3 out of 30 from 01/07/1988 to 25/05/2018 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 02/11/2017 08:24 GRIFOLS, S.A. Information on P&L Performance summary for the third quarter 2017 Register number: 258082 02/11/2017 08:22 GRIFOLS, S.A. Interim financial information La sociedad remite información sobre los resultados del tercer trimestre de 2017 Register number: 258081 30/10/2017 08:18 GRIFOLS, S.A. Information on dividends Approval of interim dividend on account of 2017 profit Register number: 257978 22/09/2017 08:26 GRIFOLS, S.A. R&D: new licenses, patents and registered trademarks Grifols has earned approval from the U.S. Food and Drug Administration for a liquid formulation of its alpha-1 antitrypsin as a replacement therapy to treat alpha-1 antitrypsin deficiency, a rare genetic disorder. Register number: 256616 28/07/2017 08:38 GRIFOLS, S.A. Interim financial information La sociedad remite información sobre los resultados del primer semestre de 2017 Register number: 255269 28/07/2017 08:36 GRIFOLS, S.A. Information on P&L Performance summary for the first half 2017 Register number: 255268 28/07/2017 08:32 GRIFOLS, S.A. Information on P&L Grifols files first half 2017 information Register number: 255267 25/07/2017 08:30 GRIFOLS, S.A. Others on corporate transactions Grifols has acquired an additional 40% equity stake in Kiro Grifols, S.L. (formerly "Kiro Robotics, S.L.") for a purchase price of EUR 12.8m. Register number: 254923 05/07/2017 08:30 GRIFOLS, S.A. Others on corporate transactions Grifols, through its 100% subsidiary Grifols Innovation and New Technologies Limited has acquired a 43.96% shareholding in GigaGen Inc. for the amount of $35M. Register number: 254260 08/06/2017 11:11 GRIFOLS, S.A. Strategic plans, profit forecasts and presentations Reunión con analistas e inversores 2017 Register number: 253050 Page 3 out of 30 «12345...»